The three-day meeting in Carlsbad, CA, included commentary from numerous executives and investors in the cell and gene therapy space. Here are some of the biggest takeaways.

Congressional scrutiny aside, ‘the rebate model remains alive and well’ as the big three pharmacy benefit managers exclude around 600 drugs each from their formularies.

As health insurance lobby launches advertising campaign to defend ‘evidence-based, market-driven tools,’ drug firms point out the connection between insurers and pharmacy benefit managers.

Cigna’s PBM, Express Scripts, is looking to “further align incentives across the pharmaceutical supply chain, consumers, and clients,” with a trio of new products available starting this summer.